| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 12/27/2006 | CN1291985C Neurotrophin production/secretion promoting agent |
| 12/27/2006 | CN1291984C 2-thio-substituted imidazole derivatives and use therof in pharmaceutical industry |
| 12/27/2006 | CN1291979C Imidazole compounds and their use as adenosine deaminase inhibitors |
| 12/27/2006 | CN1291757C Remedy for inflammatory bowel diseases |
| 12/27/2006 | CN1291756C Blood cell production via activation of hemeglobin scavenger receptor |
| 12/27/2006 | CN1291739C Penetrating liquid for field effect therapeutic equipment |
| 12/27/2006 | CN1291724C Preparation and use of injectable isopropyl acrylamide tripolymer as thrombus material and its use |
| 12/27/2006 | CN1291715C Pharmaceutical compositions containing epinastine and pseudoephedrine |
| 12/26/2006 | US7153997 N-hydroxyphenoxyphenyl derivatives of glycine or valine, e.g., N-[3,5-Dichloro-4-(4-hydroxy-3-isopropyl-5-methylphenoxy)benzoyl]glycine; treating metabolic disorders or diseases dependent upon the expression of a T3 regulated gene |
| 12/26/2006 | US7153964 Pyrimidine compounds |
| 12/26/2006 | US7153963 Phenylalanine derivatives |
| 12/26/2006 | US7153959 treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis |
| 12/26/2006 | US7153958 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 12/26/2006 | US7153887 Treatment anti-neutrophil cytoplasmic antibodies-associated vasculitis in a patient resistant to corticosteroid treatment by administering gusperimus or its salt in cycles |
| 12/26/2006 | US7153880 Substituted diphenyl heterocycles useful for treating HCV infection |
| 12/26/2006 | US7153878 Substituted thiazoles and oxazoles, e.g., 4-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid; treating atherosclerosis and diabetes and creating Syndrome X |
| 12/26/2006 | US7153865 N-type calcium channel antagonists for the treatment of pain |
| 12/26/2006 | US7153862 αv integrin receptor antagonists |
| 12/26/2006 | US7153861 5,6 -Trimethylenepyrimidin-4-one compounds |
| 12/26/2006 | US7153859 For prophylaxis and therapy of asthma, chronic obstructive pulmonary disease, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilia, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease |
| 12/26/2006 | US7153857 antiinflammatory agents; antiarthritic agents; anticancer agents |
| 12/26/2006 | US7153856 Orally administering N-(2-chloro-6-methylphenyl)-2-[4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-6-ylamino]thiazole-5-carboxamide for treating cancer |
| 12/26/2006 | US7153852 Skin disorders; antiinflammatory agents; brain disorders; chronic obstructive pulmonary disease; antiarthritic agents; inflammatory bowel disorders |
| 12/26/2006 | US7153841 Conjugates with carriers; red shifted absorption; antiproliferative and antitumor agents; benign prostatic hyperplasia; diagnosis |
| 12/26/2006 | US7153833 Therapeutic uses of SMR1 peptides |
| 12/26/2006 | US7153822 Compositions and methods for modulating connexin hemichannels |
| 12/26/2006 | US7153686 Compositions of enriched central nervous system stem cell and progenitor cell populations |
| 12/26/2006 | US7153678 Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof |
| 12/26/2006 | US7153677 Isolated, recombinantly produced, enzymatically active hyaluronan synthase; a single protein that is a dual-action catalyst that utilizes UDP-GlcA and UDP-GlcNAc to synthesize hyaluronic acid |
| 12/26/2006 | US7153649 Applying stresses to blood sampling |
| 12/26/2006 | US7153524 administering polyethylene glycol or ethylene oxide-propylene oxide copolymers, with drugs, to improve delivery in the alimentary canal |
| 12/21/2006 | WO2006135344A1 A photosensitising composition and uses thereof |
| 12/21/2006 | WO2006135109A1 Method for treatment of proliferative disease utilizing inhibition of formation of synoviolin homooligomer |
| 12/21/2006 | WO2006134989A1 Nitrogenated heterocyclic compound |
| 12/21/2006 | WO2006134970A1 Coenzyme q10-containing water-soluble composition and process for production thereof |
| 12/21/2006 | WO2006134955A1 1, 2-di(cyclic group)substituted benzene derivative |
| 12/21/2006 | WO2006134877A1 Injection |
| 12/21/2006 | WO2006134692A1 Angiogenetic agent containing adrenomedulin as the active ingredient |
| 12/21/2006 | WO2006134146A1 Orthopaedic skeletal demonstration aids |
| 12/21/2006 | WO2006058303A3 Modulators of muscarinic receptors |
| 12/21/2006 | WO2006056888A3 Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders |
| 12/21/2006 | WO2005118009A3 Transdermal delivery system for treatment of cognitive disorders |
| 12/21/2006 | US20060287539 Chemical intermediates for production of sibutramine |
| 12/21/2006 | US20060287536 Phenyl-thiophene type vitamin d receptor modulators |
| 12/21/2006 | US20060287510 Crystallization of IGF-1 |
| 12/21/2006 | US20060287502 C3b/C4b complement receptor-like molecules and uses thereof |
| 12/21/2006 | US20060287396 4-aryl quinols and analogs thereof as therapeutic agents |
| 12/21/2006 | US20060287389 Phenethanolamine derivatives for treatment of respiratory diseases |
| 12/21/2006 | US20060287374 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 12/21/2006 | US20060287371 E.g., pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-aza-13(Z)-cyclohexadecene-2,6-dione and 4S-[4R*,7S*,8R*,9R*,15R*(E)]]-4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-oxa-13-cyclohexadecene-2,6-dione; antiproliferative agents |
| 12/21/2006 | US20060287340 e.g. 5-(4-fluorophenyl)-N-[2-(1-methyl-2-oxo-1,7-diazaspiro[4,4]nonan-7-yl)-6-quinolinyl]-2-pyrimidinecarboxamide; melanin concentrating hormone receptor antagonist; central nervous system disorders, cardiovascular disorders and metabolic disorders |
| 12/21/2006 | US20060287338 Metalloproteinase inhibitor compounds |
| 12/21/2006 | US20060287329 Novel inhibitor of FXa that can be administered orally; less toxic; enzyme selectivity; high bioavailability; treatment of diseases caused by thrombi or emboli; N-(5-Chloropyridin-2-yl)-5-methoxy-2-({[trans-4-(3-oxomorpholin-4-yl)cyclohexyl]carbonyl}amino)benzamide |
| 12/21/2006 | US20060287293 1-(4-{ethyl-[2-(4-methanesulfonylphenyl)-1-methylethyl]amino}butyl)-4-methanesulfonyl-[1,4]diazepan-2-one; repiratory system disorders: asthma and chronic obstructive pulmonary disease; nervous system, muscular,urogenital, gastrointestinal disorders; antiallergens; side effect reduction |
| 12/21/2006 | US20060287286 Prophylaxis of respiratory disorders and therapy, also metod of synthesis and composition with PDE4 inhibitor, corticosteroid hibitor or anticholinergic agent |
| 12/21/2006 | US20060287268 Splice-region antisense composition and method |
| 12/21/2006 | US20060287249 Of EtO2C CH2 (R)Cgl-Aze-Pab-OH or its salt; high chemical and solid state stability; thrombin inhibitors |
| 12/21/2006 | US20060287246 Remedy for eye diseases accompanied by optic nerve injuries |
| 12/21/2006 | US20060287236 Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases |
| 12/21/2006 | US20060287235 Crystallization of IGF-1 |
| 12/21/2006 | US20060287228 Expression of active human factor IX in mammary tissue of transgenic animals |
| 12/21/2006 | US20060287223 Remodeling and glycoconjugation of peptides |
| 12/21/2006 | US20060286168 Process for producing coated preparation |
| 12/21/2006 | US20060286157 Protein mixtures for wound healing |
| 12/21/2006 | US20060286125 Immunomodulation; Yatapoxvirus polypeptide; multiple sclerosis, psoriasis, atopic dermatitis, type 1 insulin-dependent diabetes mellitus, dermatitis, Sjoigren's syndrome, encephalitis, Reiter's syndrome, psoriatic arthritis, progressive systemic sclerosis, primary biliary cirrhosis |
| 12/21/2006 | US20060286107 Parathyroid hormone antibodies and related methods |
| 12/21/2006 | US20060286087 Recombinant alpha-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| 12/21/2006 | US20060286043 Delivery of antihistamines through an inhalation route |
| 12/21/2006 | US20060286042 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone |
| 12/21/2006 | DE19843489B4 Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung Benzoylguanidine-derivatives having advantageous properties, to processes for their preparation and their use in the manufacture of medicinal products and pharmaceutical preparation containing them |
| 12/21/2006 | CA2611917A1 Injection |
| 12/21/2006 | CA2611711A1 Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor |
| 12/21/2006 | CA2607054A1 1, 2-di(cyclic group)substituted benzene derivative |
| 12/20/2006 | EP1734122A2 APO-2 ligand |
| 12/20/2006 | EP1734120A2 Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors |
| 12/20/2006 | EP1734046A1 Radiosensitizer |
| 12/20/2006 | EP1734041A2 Platelet ADP receptor inhibitors |
| 12/20/2006 | EP1734040A1 Substituted quinazoline or pyridopyrimidine derivative |
| 12/20/2006 | EP1733743A1 Preventives/remedies for cancer |
| 12/20/2006 | EP1733740A1 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient |
| 12/20/2006 | EP1733738A1 Method of preventing ultraviolet ray-induced apoptosis |
| 12/20/2006 | EP1733733A1 Regulator for adiponectin receptor expression |
| 12/20/2006 | EP1733727A1 Ferrocenecarboxamide derivatives for use as dopamine D3 ligands for the treatment of CNS disorders |
| 12/20/2006 | EP1733726A1 Pharmaceutically active isoindoline derivatives |
| 12/20/2006 | EP1733725A1 Farmaceutical formulations comprising at least one HIV protease inhibiting compound |
| 12/20/2006 | EP1733723A1 Medicine capable of inhibiting activation of transcription factor klf5 |
| 12/20/2006 | EP1733631A1 Food composition having antistress effect |
| 12/20/2006 | EP1732864A1 Radiolabeled 3-¬3- (benzoyl-amido) benzyloxy| aspartic acid derivative and method of producing the same |
| 12/20/2006 | EP1732650A1 Composition and method for cancer treatment |
| 12/20/2006 | EP1732553A1 Compounds for treating proliferative processes |
| 12/20/2006 | EP1551822B1 Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them |
| 12/20/2006 | EP1539164B1 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| 12/20/2006 | EP1506200B1 Diazabicyclic biaryl derivatives |
| 12/20/2006 | EP1456171B1 Substituted cyclohexane derivatives |
| 12/20/2006 | EP1441726B1 Derivatives of phenoxy-n-'4-(isothiazolidin-1,1-dioxid-2yl)pheny]-valerian- acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors |
| 12/20/2006 | EP1438310B1 Beta-carbolin derivatives as ptp-inhibitors |
| 12/20/2006 | EP1434762B1 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 12/20/2006 | EP1401809B1 Tryptase inhibitors |
| 12/20/2006 | EP1379235B1 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 12/20/2006 | EP1372665B1 Hormone replacement therapy method and its administration form |